Investigational Drug Information for AV-101
✉ Email this page to a colleague
What is the development status for investigational drug AV-101?
AV-101 is an investigational drug.
There have been 8 clinical trials for AV-101.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Pulmonary Arterial Hypertension, and Depressive Disorder. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Aerovate Therapeutics, and Michael E. DeBakey VA Medical Center.
There are twenty-four US patents protecting this investigational drug and two hundred and eighty-nine international patents.
Summary for AV-101
| US Patents | 24 |
| International Patents | 289 |
| US Patent Applications | 84 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2021-11-01) |
| Vendors | 19 |
Recent Clinical Trials for AV-101
| Title | Sponsor | Phase |
|---|---|---|
| Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) | Aerovate Therapeutics | Phase 2/Phase 3 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | VistaGen Therapeutics, Inc. | Phase 2 |
| AV-101 Alone and in Combination With Probenecid in Healthy Subjects | Parexel | Phase 1 |
Clinical Trial Summary for AV-101
Top disease conditions for AV-101
Top clinical trial sponsors for AV-101
US Patents for AV-101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AV-101 | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
